Long-term observation of antibody titers against SARS-CoV-2 following vaccination

Long-term observation of antibody titers against SARS-CoV-2 following vaccination

Objectives: We aimed to understand how SARS-CoV-2 antibody titer decrease following SARS-CoV-2 mRNA vaccination and to estimate the timing of booster vaccination. Study design: Six hundred sixty-two healthcare workers were administered with total of three doses of SARS-CoV-2 mRNA vaccine during the...

Full description

Bibliographic Details
Main Authors:	Kazuo Sugiyama, Chouji Suzuki, Masanori Aoyama, Nobuhiko Toyota, Nozomi Nakagawa, Makio Shozu, Kanji Nakai, Keiji Iwano
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Public Health in Practice
Subjects:	COVID-19 SARS-CoV-2 Receptor binding domain Antibody Vaccine Booster
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666535222000738

Similar Items

Effect of a booster-dose of rabies vaccine on the duration of virus neutralizing antibody titers in bovines
by: Avelino Albas, et al.
Published: (1998-08-01)

Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant
by: Rosana Wing-Shan Poon, et al.
Published: (2021-11-01)

Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose
by: Franklin Claro, et al.
Published: (2021-10-01)

Hepatitis B antibody titers in Indonesian adolescents who received the primary hepatitis B vaccine during infancy
by: Hartono Gunardi, et al.
Published: (2013-06-01)

The αTSR Domain of Plasmodium Circumsporozoite Protein Bound Heparan Sulfates and Elicited High Titers of Sporozoite Binding Antibody After Displayed by Nanoparticles
by: Xia M, et al.
Published: (2023-06-01)

Evolution of antibody profiles against SARS-CoV-2 in experienced and naïve vaccinated elderly people
by: Iván Sanz-Muñoz, et al.
Published: (2023-02-01)

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies
by: Leonardo Vargas, et al.
Published: (2022-06-01)

The cellular characterization of SARS-CoV-2 spike protein in virus-infected cells using the receptor binding domain binding specific human monoclonal antibodies
by: Chan, Conrad En-Zuo, et al.
Published: (2022)

Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination
by: Nuri Lee, et al.
Published: (2022-07-01)

Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain
by: Ping-Han Huang, et al.
Published: (2021-03-01)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
by: Jing Lian Suah, et al.
Published: (2022-12-01)

Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants
by: Yoshitomo Morinaga, et al.
Published: (2021-12-01)

The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant
by: Weeraya Thongkum, et al.
Published: (2022-06-01)

Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes?
by: Rosa Papadopoli, et al.
Published: (2020-05-01)

Multi-task learning for predicting SARS-CoV-2 antibody escape
by: Barak Gross, et al.
Published: (2022-08-01)

Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine
by: Cucunawangsih Cucunawangsih, et al.
Published: (2022-05-01)

Recombinant receptor-binding motif of spike COVID-19 vaccine candidate induces SARS-CoV-2 neutralizing antibody response
by: Hossein Samiei-Abianeh, et al.
Published: (2024-11-01)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
by: Camilo C. Roa, et al.
Published: (2024-12-01)

SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation
by: Ida Jarlhelt, et al.
Published: (2021-11-01)

Presence of neutralizing SARS‐CoV‐2 antibodies in asymptomatic population of N'Djamena, Chad
by: Andrillene Laure Deutou Wondeu, et al.
Published: (2024-01-01)

Anti-SARS-CoV-2 spike receptor binding domain (S-RBD) IgG antibodies following CoronaVac administration: a longitudinal study. Anti-SARS-CoV-2 S-RBD IgG antibodies
by: Ph. Liana, et al.
Published: (2023-02-01)

The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection
by: Heidi Syre, et al.
Published: (2022-10-01)

Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library
by: Ivette Mendoza-Salazar, et al.
Published: (2022-02-01)

A comparison of the binding sites of antibodies and single-domain antibodies
by: Gemma L. Gordon, et al.
Published: (2023-07-01)

Production and characterisation of a SARS-CoV-2 S-protein RBD homodimer with increased avidity for specific antibodies
by: A. A. Derkaev, et al.
Published: (2023-04-01)

Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV
by: Wang-Da Liu, et al.
Published: (2024-08-01)

SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore
by: Chin Shern Lau, et al.
Published: (2022-02-01)

Postbooster Antibodies from Humans as Source of Diphtheria Antitoxin
by: Jesús F. Bermejo-Martin, et al.
Published: (2016-07-01)

Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico
by: José Antonio Montes-González, et al.
Published: (2023-04-01)

Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme
by: Andrea Kanizsai, et al.
Published: (2023-01-01)

Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2
by: Zsofia Hevesi, et al.
Published: (2022-03-01)

Anti-SARS-CoV-2 Antibodies Level and COVID-19 Vaccine Boosters among Healthcare Workers with the Highest SARS-CoV-2 Infection Risk—Follow Up Study
by: Dagny Lorent, et al.
Published: (2024-04-01)

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses
by: Lu Zhang, et al.
Published: (2022-09-01)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
by: Tao Li, et al.
Published: (2023-12-01)

Reduction of adverse reactions and correlation between post-vaccination fever and specific antibody response across successive SARS-CoV-2 mRNA vaccinations
by: Naoki Tani, et al.
Published: (2024-06-01)

Rabies Vaccination for Sheep and Goats: Influence of Booster on Persistence of Antibody Response
by: Sarah Weyl Feinstein, et al.
Published: (2024-10-01)

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
by: Thomas Perkmann, et al.
Published: (2023-08-01)

Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination
by: Latha Dulipsingh, et al.
Published: (2023-02-01)

Identification of conserved linear epitopes in the SARS-CoV-2 receptor-binding region using monoclonal antibodies
by: Yujie Yang, et al.
Published: (2023-06-01)

Retrospective Cohort Study of COVID-19 in Patients of the Brazilian Public Health System with SARS-CoV-2 Omicron Variant Infection
by: Thiago B. Murari, et al.
Published: (2022-09-01)